GHK-Cu is a naturally occurring tripeptide-copper complex that declines significantly with age. One of the smallest research peptides by molecular size, it demonstrates broad biological activity including collagen remodeling, gene expression regulation, and wound healing promotion across multiple preclinical models.
GHK-Cu (Copper Peptide): Mechanism of Action and Preclinical Research Overview Read More »
NAD+ is a coenzyme found in every living cell, central to energy metabolism, DNA repair, and sirtuin activation. Declining NAD+ levels with age have made it one of the most actively studied molecules in longevity science. This overview covers key mechanisms and published research findings.
TB-500 (Thymosin Beta-4) is one of the most abundant intracellular peptides in mammalian cells, studied extensively for its roles in actin dynamics, angiogenesis, and tissue regeneration across cardiac, musculoskeletal, and wound healing models.
TB-500 (Thymosin Beta-4): Mechanism of Action and Preclinical Research Overview Read More »
CJC-1295 and Ipamorelin target two independent GH secretion pathways — the GHRH receptor and ghrelin receptor respectively — producing synergistic growth hormone release in preclinical models. This overview covers both mechanisms, published clinical data, and the scientific rationale for their combined study.
Tesamorelin is a synthetic GHRH analog and the only peptide in its class with FDA approval, providing a uniquely robust body of human clinical data. This overview covers its pituitary mechanism, pivotal trial findings in visceral fat reduction, and emerging research in cognitive function and NAFLD.
Tesamorelin: GHRH Analog Research Overview and Clinical Data Summary Read More »
BPC-157 is a synthetic pentadecapeptide with one of the largest bodies of preclinical research in its class, spanning gastrointestinal protection, tendon and ligament repair, and neuroprotection. This overview covers its key mechanisms including VEGF pathway activation, nitric oxide modulation, and FAK-paxillin signaling.
BPC-157: Mechanism of Action and Preclinical Research Overview Read More »
Retatrutide (LY3437943) is a triple GIP, GLP-1, and glucagon receptor agonist developed by Eli Lilly, representing the next generation of metabolic research compounds beyond dual agonists like tirzepatide. This overview covers its unique triple-receptor mechanism, Phase 2 trial data showing up to 24.2% body weight reduction, and current Phase 3 research status.
Retatrutide (LY3437943): Mechanism of Action and Current Clinical Research Overview Read More »
